KIMS Krishna Institute of Medical Sciences Q4 FY25 results (Jan–Mar 2025) and concall
KIMS delivered a strong performance in FY25, characterized by robust revenue growth and margin expansion despite the drag from newly commissioned units. The company is in a heavy expansion phase, entering new markets like Maharashtra and Kerala while consolidating its lead in Telangana and Andhra Pradesh. Management is leveraging high-end medical technology (Gamma Knife, TULSA-PRO) to drive ARPOB and expects new units to reach EBITDA break-even within 12 months of commissioning.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 363 | 348 | 346 |
| EBITDA | 111 | 103 | 109 |
| Net profit | 72 | 76 | 94 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
